Table 1 Clinical and endoscopic characteristics of patients

Gender, male, n (%)

39 (68.40)

10 (76.90)

29 (65.9)

0.45

Mean age ± SD (years)

40.02 ± 12.32

50.23 ± 11.50

37.00 ± 10.94

< 0.001

Hypertension, yes/no

7/50

2/11

5/39

0.70

Diabetes, yes/no

3/54

1/12

2/42

0.65

Number of previous bleeds, mean ± SD

2.88 ± 2.56

3.23 ± 2.00

2.77 ± 2.71

0.58

 1/2/ ≥ 2

9/21/22

0/7/6

9/14/16

0.276

Jaundice, yes/no

17/40

9/4

8/36

< 0.001

Splenomegaly, yes/no

37/20

5/8

32/12

0.02

 Stage 1/2/3/4/5

1/13/11/7/5

1/4/0/0/0

0/9/11/7/5

0.016

Ascites, yes/no

14/43

5/8

9/35

0.19

 Grade 1/2/3

3/5/6

1/1/3

2/4/3

0.37

Causes of cirrhotic PH, n (%)

 Alcohol

5 (8.80)

5 (38.46)

-

-

 Hepatitis B virus

4 (7.00)

4 (30.77)

-

-

 Hepatitis C virus

1 (1.80)

1 (7.69)

-

-

 Alcohol/hepatitis B virus

1 (1.80)

1 (7.69)

-

-

 Autoimmune hepatitis

2 (3.50)

2 (15.39)

-

-

Causes of non-cirrhotic PH, n (%)

 Hepatosplenic schistosomiasis

40 (70.20)

-

40 (90.91)

-

 Portal thrombosis

4 (7.00)

-

4 (9.09)

-

Grade of esophageal varix III/II

55/2

13/0

42/2

0.43

Red signs, yes/no

22/35

5/8

17/27

0.99

Child–Pugh score, mean ± SD

8.38 ± 2.29

8.38 ± 2.29

-

-

Child–Pugh class, A/B/C

3/8/2

3/8/2

-

-

Dose de propranolol (mg/jour), mean ± SD

108.07 ± 38.52

86.15 ± 22.19

114.55 ± 40.08

0.02

Propranolol dose (mg/day), 80/160

37/20

12/1

25/19

0.02

Indication for EVL, n (%)

 Primary prevention

3 (5.30)

0 (0.00)

3 (6.80)

0.33

 Secondary prevention

54 (94.70)

13 (100.00)

41 (93.20)

Number of sessions, mean ± SD

2.40 ± 1.03

2.31 ± 1.03

2.43 ± 1.04

0.71

Time between EVL sessions (months), mean ± SD

1.30 ± 0.46

1.31 ± 0.48

1.30 ± 0.46

0.93

Follow-up time (months), mean ± SD

6.28 ± 6.54

7.69 ± 7.27

5.86 ± 6.33

0.38